產(chǎn)品詳情
簡單介紹：
Anti-SPOCD1抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購！我公司長期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-SPOCD1抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-SPOCD1
Cat. Number:
Anti-SPOCD1抗體KL-17682R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
SPOCD1 is a 1,216 amino acid protein that contains one SPOC domain and one TFIIS central domain. SPOCD1 exists as five alternatively spliced isoforms, with isoform 1 showing expression in lung. The gene that encodes SPOCD1 contains 25,630 bases and maps to human chromosome 1p35.2. Spanning about 260 Anti-SPOCD1抗體million base pairs and making up 8% of the human genome, chromosome 1 is the largest human chromosome. There are about 3,000 genes on chromosome 1, and considering the great number of genes there are also a large number of diseases associated with chromosome 1. Stickler syndrome, Parkinsons, Gaucher disease and Usher syndrome are also associated with chromosome 1 and aberrations in chromosome 1 are found in a variety of cancers including head and neck cancer, malignant melanoma and multiple myeloma.
Also known as:
FLJ25348; RP11-84A19.1; Anti-SPOCD1抗體SPOC domain-containing protein 1; SPOC1_HUMAN; SPOCD1.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, .
●
Immunogen: KLH conjugated synthetic peptide derived from human SPOCD1.
●
Predicted Molecular Weight: 130kDa.
Storage:
Shipped at 4℃, Store at -20℃ Anti-SPOCD1抗體(Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-SPOCD1抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-SPOCD1抗體
Optimal working dilutions must be determined by the end user.
